Other
Indomethacin
0
Pipeline Programs↗
3
Active Trials↗
3
Companies Involved↗
Indomethacin is an early-stage landscape with 0 programs across 3 companies. The most active players are Iroko Pharmaceuticals, LLC, Bayer, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
28
clinical trials
Completed19 · 68%
Terminated3 · 11%
Unknown status2 · 7%
Not yet recruiting2 · 7%
Recruiting1 · 4%
Withdrawn1 · 4%
Clinical Trials
Trial Activity
28 trials
Indomethacin vs Diclofenac for Preventing PEP
Recruiting·—·N/A·NCT07071441·4,050 enrolled
Dose-escalation of Rectal Indomethacin for Preventing PEP
Not yet recruiting·TThe First Affiliated Hospital of Anhui Medical University·Phase 4·NCT07247682·1,036 enrolled
Indomethacin Use in Pain Relief During Intrauterine Device Insertion
Completed·—·Phase 4·NCT02711358·120 enrolled
Rectal Indomethacin vs Intravenous Ketorolac
Completed·—·Phase 4·NCT05664074·192 enrolled
Indomethacin and Mechanisms Underlying Risk of Falling
Completed·—·Phase 4·NCT00462111·20 enrolled
Papillary Epinephrine Injection Combined With Rectal Indomethacin
Completed·—·Phase 4·NCT07173179·504 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)